Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Acneiform rash is frequently observed in patients undergoing cancer treatment with anti-epidermal growth factor receptor (EGFR) antibody drugs and can often necessitate treatment discontinuation. However, the specific changes in skin parameters resulting from anti-EGFR antibody drug administration are poorly understood. Therefore, this study aimed to longitudinally and quantitatively evaluate the changes in skin parameters (transepidermal water loss [TEWL], hydration level, and sebum level) caused by anti-EGFR antibody drugs and investigate their potential as control markers for skin disorders.
Methods: This prospective study included 12 patients with colorectal cancer who received anti-EGFR antibody drugs for the first time. The assessment items included the grade of acneiform rash and skin parameters (TEWL, hydration level, and sebum level), which were observed for up to 6 weeks after administration of the medication.
Results: The enrolled patients were classified into two groups based on the grade of acneiform rash caused by anti-EGFR antibody drugs: "Grade 1 and lower," and "Grade 2 and higher." The skin parameters were compared between these groups. The results showed that in the "Grade 2 and higher" group, TEWL in the face (at week 2 of administration), chest (baseline, weeks 2 and 6 of administration), and back (at week 2 of administration) were significantly higher than those in the "Grade 1 and lower" group. However, the two groups showed no significant differences in hydration or sebum levels at any time point.
Conclusion: TEWL can serve as a marker for acneiform rashes induced by anti-EGFR antibody drugs during cancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00280-023-04619-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Label-free immunoassay based on chemiluminescence-functionalized magnetic mesoporous nanoparticles for rapid detection of neuron-specific enolase.
Mikrochim Acta
September 2025
The Third Affiliated Hospital of Anhui Medical University, The First People's Hospital of Hefei, Binhu Hospital of Hefei, Hefei, 230061, P. R. China.
Lung cancer, as one of the cancers with the highest morbidity and mortality rates in the world, requires accurate detection of its vital serum marker, neuron-specific enolase (NSE), which is a key challenge for early detection of lung cancer. However, traditional chemiluminescence immunoassay (CLIA) methods rely on labeled antibodies (Abs) and suffer from complex operations and high costs. In this work, a label-free CLIA based on CL-functionalized mesoporous magnetic nanoparticles (CuFeO@mSiO-Cys-Luminol-Au NPs) is developed for the rapid and sensitive detection of NSE.
View Article and Find Full Text PDFInter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer.
Mol Diagn Ther
September 2025
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.
Background And Objective: Sacituzumab govitecan, an anti-trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate, has been approved by both the US Food and Drug Administration and European Medicines Agency for patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. Although TROP2 evaluation is not required for patient selection, survival data from the ASCENT trial show improved response rates in patients with high TROP2 expression by immunohistochemistry. However, there is no standardized testing assay for these patients.
View Article and Find Full Text PDFImmune-mediated necrotizing myopathy: an emerging disorder.
Neurologia (Engl Ed)
September 2025
Unidad de ELA-Neuromuscular, Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, Spain; IiSGM, Instituto de Investigación Sanitaria Gregorio Marañón.
Objectives: To describe the main features and the clinical management of a cohort of patients with immune-mediated necrotizing myopathy (IMNM).
Methods: We conducted an observational, monocentric, retrospective study of IMNM patients diagnosed in the Neuromuscular Unit of a tertiary hospital in Madrid (Spain) between 2013 and 2021.
Results: Sixteen IMNM cases were diagnosed, with a median age of 71.
Contemporary trends in targeted protein degradation for neurodegenerative diseases.
Eur J Med Chem
August 2025
Amity Institute of Pharmacy, Amity University Haryana, 122413, India. Electronic address:
Neurodegenerative diseases (NDs), including Alzheimer's, Huntington's, and Parkinson's disease, are associated with significant declines in cognitive function and mobility. The accumulation of misfolded proteins such as β-amyloid, tau, α-synuclein, and polyglutamates is a key factor in the progression of these conditions. Unfortunately, traditional small-molecule drugs face major obstacles in effectively targeting these proteins.
View Article and Find Full Text PDFG-protein coupled receptors in neuroinflammation, neuropharmacology, and therapeutics.
Biochem Pharmacol
September 2025
Chemical Biology Laboratory, School of Basic Sciences, Indian Institute of Technology Bhubaneswar, Odisha 752050, India. Electronic address:
The G protein-coupled receptors (GPCRs) represent one of the most pharmacologically targeted classes of seven-transmembrane (7TM) receptors, identified through whole genome sequencing of humans. GPCRs transduce extracellular stimuli and signals into intracellular responses, enabling precise cellular communication for physiology and homeostasis. Given their ability to sense a variety of ligands, GPCRs regulate a plethora of physiological functions, such as sensory perception, hormonal regulation and metabolism, growth and development, cardiovascular and reproductive regulation.
View Article and Find Full Text PDF